ArticleJournal of gastrointestinal oncology2026

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.

Atsushi Ono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.